about
Immuno-Modulatory Effect and Therapeutic Potential of Brugia malayi Cystatin in Experimentally Induced ArthritisBrugia malayi soluble and excretory-secretory proteins attenuate development of streptozotocin-induced type 1 diabetes in mice.Therapeutic potential of the immunomodulatory proteins Wuchereria bancrofti L2 and Brugia malayi abundant larval transcript 2 against streptozotocin-induced type 1 diabetes in mice.Immunization with Wuchereria bancrofti Glutathione-S-transferase Elicits a Mixed Th1/Th2 Type of Protective Immune Response Against Filarial Infection in Mastomys.Brugia malayi cystatin therapeutically ameliorates dextran sulfate sodium-induced colitis in mice.Filarial Abundant Larval Transcript Protein ALT-2: An Immunomodulatory Therapeutic Agent for Type 1 Diabetes.Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis.Chimeric Epitope Vaccine from Multistage Antigens for Lymphatic Filariasis.Wuchereria bancrofti 20/22 a homologue of abundant larval transcript L3 stage filarial antigen: molecular and immunological characterization.Immunoprophylaxis of multi-antigen peptide (MAP) vaccine for human lymphatic filariasis.Immunodiagnostic potential of Wuchereria bancrofti L1 antigen-based filarial immunoglobulin G4 detection assayEvaluating the Vaccine Potential of a Tetravalent Fusion Protein (rBmHAXT) Vaccine Antigen Against Lymphatic Filariasis in a Mouse Model.Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primatesSXP-RAL Family Filarial Protein, rWbL2, Prevents Development of DSS-Induced Acute Ulcerative ColitisCystatin from Filarial Parasites Suppress the Clinical Symptoms and Pathology of Experimentally Induced Colitis in Mice by Inducing T-Regulatory Cells, B1-Cells, and Alternatively Activated MacrophagesWuchereria bancrofti macrophage migration inhibitory factor-2 (rWbaMIF-2) ameliorates experimental colitis
P50
Q36764144-1A0423E8-0509-4476-92DD-1BBBD1FB8B26Q38872408-93D238E2-73CA-4451-B7B2-FF6FA0BAEF7AQ38872412-DBE94CB9-3239-4486-AA1E-DDB3779E2CB5Q38875510-40B7AB6C-4C53-44A5-8533-D6D9A5CF57C5Q39133230-92A40C8D-3001-4CED-A023-E4FF5D0EEB46Q39388911-DBE10E7C-A61B-4412-98BB-995BE114E1D8Q40084746-7BA48F5F-F8EC-4F2A-ACF2-F20223BC49D4Q41106181-957CAF02-3155-47A8-9B4E-109306D5F774Q44278073-C1BAF474-302A-400D-B9E6-79B08309099BQ50863204-ADD553AA-2E23-4836-893E-4D179E7CA5B6Q57466412-7C2722DE-B1A6-46CA-AF3D-2621F640C010Q64925179-6089694A-A4CE-497D-A569-A05FD660F3B0Q89049413-9764BB12-8883-48DD-9868-7241DA4D684DQ90725003-16CD8A01-4CB9-4250-B59F-A7ABE0420276Q91093622-2E3D47FC-7681-4A9C-88B2-516EBEA216E4Q92903695-94876E57-4F94-4CDC-B1C0-D513BE2A42AC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vishal Khatri
@ast
Vishal Khatri
@en
Vishal Khatri
@es
Vishal Khatri
@nl
type
label
Vishal Khatri
@ast
Vishal Khatri
@en
Vishal Khatri
@es
Vishal Khatri
@nl
prefLabel
Vishal Khatri
@ast
Vishal Khatri
@en
Vishal Khatri
@es
Vishal Khatri
@nl
P106
P1153
56396373400
P31
P496
0000-0002-5154-6260